Clinical Experiences of Physicians and Nurses Recognising Neuroleptic Malignant Syndrome in Psychiatric Hospitals: An Interpretative Phenomenological Study
(1) Universitas Muhammadiyah Semarang (2) Universitas Muhammadiyah Semarang (3) Universitas Muhammadiyah Semarang (*) Corresponding Author
Abstract
Neuroleptic malignant syndrome (NMS) and metabolic neurological disorders can both present with altered consciousness, creating a diagnostic challenge in psychiatric emergency and intensive care services. This qualitative study explored how physicians and nurses experienced early recognition and management of patients with deteriorating consciousness in two referral psychiatric hospitals in Central Java, Indonesia. An interpretative phenomenological design involved 14 clinicians: two specialist physicians, six general practitioners and six nurses. Semi-structured interviews, reflective observation and a focus-group discussion were used to examine lived experiences; the thesis describes interpretative phenomenological analysis supported by triangulation, member checking and an audit trail. Its findings were organised into four domains: the experience of managing acute deterioration, early detection and differential diagnosis, interprofessional collaboration and staff development, and clinical reflection. Participants’ reported accounts highlighted the challenge of distinguishing NMS from metabolic or other neurological conditions when characteristic features develop over time. Familiar clinical warnings included hyperthermia, muscle rigidity, altered mental status and autonomic dysfunction; early review of causative medication and escalation to supportive management were central clinical concerns. The findings indicate that structured recognition pathways, clear professional responsibilities and reflective team learning warrant consideration, without establishing the effectiveness of any specific clinical protocol. The interpretations are contextual and should not be generalised as estimates of the prevalence of NMS or of treatment effects.
Orsolini L, Volpe U. Expert guidance on the differential diagnosis of neuroleptic malignant syndrome. Expert Rev Neurother. 2025;25(2):125–132. doi:10.1080/14737175.2024.2417414
Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011. doi:10.4088/JCP.10m06438
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi:10.1093/intqhc/mzm042
O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245–1251. doi:10.1097/ACM.0000000000000388
Chen A, Bae M. Lorazepam in Managing Atypical Neuroleptic Malignant Syndrome: A Systematic Review of Case Reports. West J Emerg Med. 2025;26(5):1446–1453. doi:10.5811/westjem.41514
Zhan C, Zahrli T, Hoover B. Atypical Neuroleptic Malignant Syndrome Without Rigidity and With Cardiac Troponin Elevation. J Acad Consult Liaison Psychiatry. 2025;66(5):460–463. doi:10.1016/j.jaclp.2025.08.001